Live attenuated mumps vaccines based on live attenuated virus strains including the Jeryl-Lynn, RIT 4385, Leningrad-3, Leningrad-Zagreb, Urabe Am9, S79, Rubini, and others, have been available since the 1960s. However, due to the low level of seroconversion obtained with the Rubini strain, WHO has recommended that this strain should not be used in national immunization programmes. These vaccines are produced by growing the virus in cell cultures or in embryonated chicken eggs. The virus is then purified, formulated with a stabilizer such as gelatine or sorbitol and lyophilized. Mumps vaccines are available as a monovalent vaccine, a bivalent measles-mumps vaccine, or as a trivalent measles-mumps-rubella vaccine (MMR). 

• Vaccination with a mumps-containing vaccine is the most effective and established method to prevent mumps illness. WHO recommends MMR vaccines for countries with mature immunization programmes, in line with the coverage targets recommended for measles–rubella (MR) vaccination. 
• Mumps control strategies should be closely integrated with existing measles and rubella control and elimination goals. Countries able to achieve and sustain high MR vaccine coverage, and to reach measles and rubella control and/or elimination levels, should consider introducing mumps vaccine into their national immunization programmes. 
• Countries considering MMR introduction should weigh the costs (including vaccine procurement), surveillance for disease incidence and adverse events, health worker training, public communication, and potential savings.  
• When included in a national routine programme, mumps vaccine should be given in combination with measles and rubella (MMR or MMRV) and follow the same schedule.